India rejects Pfizer's Xeljanz patent again; Opdivo-Yervoy combo safe, effective in lung cancer: study;

@FiercePharma: Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. More from FiercePharmaAsia  | Follow @FiercePharma

@CarlyHFierce: ICYMI Friday: AstraZeneca scores FDA nod for long-term Brilinta use. Article | Follow @CarlyHFierce

India has once again rejected the patent on Pfizer's ($PFE) rheumatoid arthritis drug, Xeljanz. Report

> Bristol-Myers Squibb's ($BMY) Opdivo can be safely and effectively paired with relatively low and infrequent dosages of the company's other immunotherapy, Yervoy, for patients with previously untreated lung cancer, early-stage study results say. More

> Mylan ($MYL) has launched a generic of Bayer's Yasmin birth control tablets. Report

> Stallergenes has merged with Ares Allergy. More

> Hikma Pharmaceutical has struck a deal for Egyptian pharma EIMC United. Report

> The Scottish Medicines Consortium has approved the use of Roche's Avastinin tandem with paclitaxel chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. More

Medical Device News

@FierceMedDev: ICYMI from FierceDiagnostics: Focus Diagnostics gets FDA blessing to expand label for herpes test. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI Friday: Allergan to grab AqueSys for $300M+ to add minimally invasive glaucoma microshunt. Article | Follow @StacyALawrence

@EmilyWFierce: ICYMI from FiercePharma: Novartis snags EU approval for multiple myeloma med Farydak. Report | Follow @EmilyWFierce

> GSK-backed SetPoint raises $15M to advance anti-inflammatory, neuromodulation device. Article

> Novartis CEO: Smart contact lenses 'progressing well' with first human trials set for 2016. Report

Biotech News

@FierceBiotech: Purdue puts up $213M for a novel pain drug from VM Pharma. Report | Follow @FierceBiotech

@JohnCFierce: AstraZeneca nabs priority review voucher as Wellstat bags FDA OK. Report | Follow @JohnCFierce

@DamianFierce: NYT editorial takes a weird, non-systemic middle ground on PCSK9 pricing. Article | Follow @DamianFierce

> Bristol-Myers' latest PD-1 win could pave the path to earlier use. Story

> J&J heads to Toronto with incubation plans for up to 50 upstart biotechs. Article

> Sanofi backs $38M E round for Langer's Selecta. Report

Animal Health News

> Report: Bees self-medicate to protect against parasites. More

> Nexvet doubles down on R&D spending as net loss widens. Report

> Veterinarian's op-ed piece says antibiotic ban taking tools away from vets. Article

> New mobile app allows virtual veterinary consultations. Item

> UC Davis veterinarian pushes 'One Health' system for scientific literature. Story

Biotech IT News

> NIH commits $49M to fuel fusion of genomic data and EHRs. News

> Labfolder taps investors for cash to develop ELN system. Report

> Thermo Fisher rolls out Ion S5 sequencer in play for clinical trial sector. Story

> CD Genomics adds HiSeq X Ten to suite of tools for sequencing services. Item

> Google hooks up with Sanofi to continue diabetes drive. Article

Drug Delivery News

> Gene therapy approach for T1 diabetes could alter immune system to boost insulin. Report

> Sanofi looking to expand U.K. plant that does contract manufacturing of inhaled meds. Story

> Columbia U. team delivers small liquid drug doses to the lungs for targeted treatment. More

> Study finds e-cigarettes are being used to vaporize pot. Item

> Generic alternative to Novartis' transdermal patch for Alzheimer's hits the market. Article

Pharma Manufacturing News

> Recipharm to buy Alcon plant as part of manufacturing agreement. News

> GSK runs into supply issues after China plant damaged by nearby explosion. More

> MSF warns that Sanofi leaving antivenom market will lead to treatment crisis. Report

> Cipla gets first U.S. manufacturing plant with InvaGen buy. Article

> U.K. generics maker starts plant in Alabama. Story

Pharma Asia News

> Japan's PAFSC gives nods to Takeda's glatiramer, MSD's omarigliptin. News

> Samsung Bioepis wins South Korea nod for SB4, etanercept biosimilar. Story

> India denies Pfizer application for additional Xeljanz patents. More

> Japan's Chugai notes U.S. FDA breakthrough designation for ACE910. Item

> Hutchison MediPharma's fruquintinib notches a second with proof-of-concept result. Article

And Finally... GlaxoSmithKline ($GSK) has started work on its largest Indian tablet manufacturing factory. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.